ArticlePloS one2026
Mechanisms of transcutaneous bilateral auricular vagus nerve stimulation in treating functional dyspepsia through promoting M2 macrophage polarization.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFunctional dyspepsia (FD) is characterized by duodenal mucosal barrier dysfunction and chronic low-grade inflammation. Macrophage polarization imbalance, particularly the predominance of pro-inflammatory M1 over anti-inflammatory M2 phenotypes, contributes significantly to FD pathogenesis. Transcutaneous auricular vagus nerve stimulation (taVNS) has emerged as a promising non-invasive therapeutic approach for gastrointestinal disorders.
objectiveThis study aimed to investigate the therapeutic mechanisms of taVNS in FD treatment, specifically focusing on its effects on M2 macrophage polarization and the roles of metabolic regulator UCP2 and transcription factor GATA3 in this process.
methodsMale C57BL/6J mice (n = 27) and Gata3∆mac mice (n = 9), totaling 36 mice were used to establish an FD model through multi-factorial stress induction and were divided into four experimental groups. taVNS treatment was administered for 2 weeks. Feeding behavior, duodenal mucosal inflammatory cytokines, inflammatory markers, macrophage polarization markers, and intestinal barrier function were assessed. Gata3∆mac + taVNS mice were used to determine the transcription factor's role in taVNS-mediated effects.
resultsTaVNS treatment significantly improved feeding behavior in FD mice. At the duodenal mucosal level, taVNS markedly reduced the elevated IL-1βlevels and restored the suppressed TGF-β1 levels. TaVNS also promoted M2 macrophage polarization, as evidenced by decreased Nos2 expression and increased Arg1 expression. TaVNS partially restored Ucp2 and Gata3 expression relative to FD mice, elevated the expression of tight junction ZO-1 to relieve duodenal tight junction impairment linked to barrier dysfunction, and modulated inflammatory responses (decreased TNF-α, increased IL-10). The therapeutic effects of taVNS were significantly attenuated in Gata3∆mac + taVNS mice, confirming the critical role of GATA3 in mediating taVNS-induced M2 polarization.
conclusionstaVNS promotes M2 macrophage polarization to treat FD through mechanisms involving both metabolic regulation (UCP2) and transcriptional control (GATA3). These findings provide novel insights into the immunometabolic mechanisms underlying taVNS therapy and support its clinical application for FD management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.